Key Points for Decision Makers {#FPar1}
==============================

Sertraline is often prescribed by GPs for symptoms of depression, but it is unclear which patients benefit most.We found insufficient evidence that either symptom severity or duration could be used by GPs to better target the prescribing of sertraline.Sertraline is probably a cost-effective treatment for depressive symptoms in UK primary care.

Introduction {#Sec1}
============

Depression is the leading cause of disability worldwide \[[@CR1]\], affecting 4.4% of the world's population, or 322 million people \[[@CR2]\]. Between 2005 and 2015, the number of people living with depression increased by 18.4% \[[@CR1]\]. First-line pharmacological treatment of depression is usually with selective serotonin reuptake inhibitor (SSRI) antidepressants, which provide small beneficial effects over placebo \[[@CR3]\]. Use of antidepressants has increased dramatically in recent years, particularly in high-income countries. In 2016, 65 million antidepressant items were prescribed in England, more than double the number prescribed ten years earlier (31 million) \[[@CR4]\]. The associated healthcare costs of increased use of antidepressants are considerable, despite the introduction of cheaper generic SSRI equivalents. In 2016, primary care prescriptions of antidepressants in England cost the National Health Service (NHS) £266.6 million \[[@CR4]\].

Depression is typically managed by general practitioners (GPs), with the exception of a small proportion of cases that require specialist mental or social care services \[[@CR5]\]. Management options include active monitoring, low-intensity psychosocial interventions, group cognitive behavioural therapy and drug treatment \[[@CR6]\]. The decision to prescribe is generally based on clinical judgement of patients' symptoms and not on the results of standardised scales or questionnaires. Patients may be considered mildly, moderately or severely depressed, depending on their associated symptoms \[[@CR5], [@CR7]\]; however, it is unclear which patient groups are most likely to benefit from treatment with SSRIs. Patients with mild depressive symptoms are commonly prescribed antidepressants despite not meeting International Classification of Diseases (ICD-10) criteria for depression \[[@CR5], [@CR8]\], and there is limited evidence to support the use of antidepressants in this population \[[@CR9]\]. It has been proposed that patients with more severe symptoms may benefit more from antidepressants, although the evidence is not clear-cut \[[@CR10]--[@CR14]\]. Patients with dysthymia---depression that is present for two or more years but does not meet diagnostic criteria \[[@CR15]\]---might also benefit more from antidepressants. Previous studies were not designed to explore the cost-effectiveness of antidepressants by severity and duration of depression.

We undertook a large pragmatic randomised controlled trial (the PANDA RCT---What are the indications for Prescribing ANtiDepressants that will leAd to a clinical benefit?) to investigate the clinical effectiveness of a commonly prescribed SSRI, sertraline, versus placebo, and to explore the influence of severity and duration of depressive symptoms on response to sertraline compared with placebo in people presenting to primary care with depression. The results of the RCT are detailed in Lewis et al. \[[@CR16]\]. In this paper, we estimated the cost-effectiveness of sertraline in comparison with placebo at the end of 12 weeks of follow-up in relation to the baseline severity and duration of depressive symptoms. A secondary analysis estimated the cost-effectiveness of sertraline in comparison with placebo in all patients, irrespective of severity or duration.

Methods {#Sec2}
=======

The published trial protocol provides full details of eligibility criteria, recruitment, randomisation, treatment regimens and assessment methods \[[@CR17]\]. In brief, PANDA is a randomised, double-blind, placebo-controlled trial in which participants are individually randomised to sertraline or placebo. Eligible participants aged between 18 and 74 were identified in primary care with depression or low mood during the past 2 years and had not received antidepressant or anti-anxiety medication in the previous 8 weeks. Trial participants were recruited from 179 primary care surgeries in four UK sites. Participants were randomised to receive either sertraline or matching placebo, starting at 50 mg daily for 1 week, increasing to 100 mg daily for up to 11 weeks (with the option of increasing to 150 mg if required). Sertraline is a cheap off-patent medication (approximately £0.80--1.00 per 28 tablets) \[[@CR18]\]. The primary outcome was depressive symptoms measured by the Patient Health Questionnaire 9 (PHQ-9) at 6 weeks postrandomisation. The clinical effectiveness findings of the PANDA trial have been reported in detail \[[@CR16]\], and are briefly summarised here in the "[Results](#Sec6){ref-type="sec"}" section.

The primary economic analysis took an NHS and personal social services (PSS) perspective. A secondary analysis was undertaken from the perspective of individual patients, accounting for costs such as expenditure on private health care. We also considered the cost to society of work absences. The time horizon for the economic analysis was up to 12 weeks post-randomisation, reflecting the duration of follow-up in the trial. As the follow-up period does not extend beyond one year, discounting of costs and benefits was not applied. The analysis plan was agreed with the trial steering committee and was deposited in UCL Discovery \[[@CR19]\].

Estimating Benefits {#Sec3}
-------------------

The primary economic outcome measure was quality-adjusted life years (QALYs) derived from utility scores, obtained using the EQ-5D-5L quality of life instrument \[[@CR20]\]. EQ-5D-5L questionnaires were completed by participants prior to randomisation (baseline) and at 2, 6 and 12 weeks post-randomisation. Baseline and research follow-up assessments took place at the participant's home, general practice, or at university premises. Utility scores were derived from responses to the EQ-5D-5L using valuations obtained from an English population \[[@CR21]\]. We used linear interpolation of responses at baseline and at 2, 6 and 12 weeks to estimate QALYs over the 12-week period, adjusting for baseline EQ-5D-5L scores in regression analyses as recommended in the literature \[[@CR22]\].

Estimating Costs {#Sec4}
----------------

For the primary analysis, data were collected on health service use, including primary care consultations, sertraline, other prescribed medication, hospital admission, outpatient attendance, emergency department attendance and community-based care. For secondary analyses, we also included productivity losses due to mental health problems and personal costs (e.g. payments for additional care). Primary care consultations were captured through electronic downloads of GP records. Manual data extraction was used as a backup if GP records did not support automatic downloads. NHS secondary care, community care, care from social services, time off work and patient personal resource use during trial follow-up was captured using patient-reported questionnaires completed at 2, 6 and 12 weeks.

The cost of medications was estimated from the British National Formulary \[[@CR23]\]. Community and primary care costs were based on national estimates \[[@CR24]\]. Codes for Healthcare Resource Groups (groups of events that have been judged to consume similar levels of resources) were assigned to secondary care contacts and were costed based on aggregate national reference costs where available (for example, ultrasound) \[[@CR25]\]. Productivity costs were estimated based on national average weekly earnings stratified by sex \[[@CR26]\]. All costs are reported for the financial year 2017/18 in pounds sterling (£) and adjusted for inflation using the Hospital and Community Health Services Index where necessary \[[@CR24]\].

Cost-Effectiveness Analysis {#Sec5}
---------------------------

A cost-effectiveness analysis was conducted using the intention-to-treat principle, comparing the two groups as randomised and including all patients in the analysis. This analysis estimated the cost-effectiveness of sertraline and how the net monetary benefit (NMB) of sertraline varies with baseline severity of depression and with symptom duration. NMB is a summary statistic used to present cost-effectiveness results. It estimates the value of an intervention in monetary terms using a predefined willingness to pay threshold for a unit of benefit, typically QALY. An intervention is said to be cost-effective if the NMB is positive. The NMB is recommended for use in identifying heterogeneity in cost-effectiveness between subgroups as, unlike the incremental cost-effectiveness ratio (ICER) that was specified in the trial protocol, the NMB is a linear combination of individual patient costs and QALYs that facilitates regression analysis using subgroup interaction terms \[[@CR27]\].

Data cleaning was undertaken prior to the unblinding of the economic researcher to the study groups. This involved the correction of obvious 'free text' response errors (e.g. misspelt drug names) and group coding of similar resource items to enable unit costing. Multiple imputation was subsequently undertaken for missing data. The primary analysis was based on imputed datasets and included all participants \[[@CR28], [@CR29]\]. We implemented multiple imputation by chained equations on data that were assumed missing at random. The imputation model was stratified by trial arm and included complete demographic data (e.g. age, ethnicity, financial stability, marital status) alongside clinical outcome variables (on severity and duration of depressive symptoms) at baseline, utility score at baseline, cost and utility variables with missing data, and site practice (i.e. London, Bristol, Liverpool, York). We imputed costs at the aggregate level (e.g. total NHS and PSS costs). We imputed utility data for each follow-up period and used these to generate QALY estimates. The number of imputations (*n* = 40) was selected to be greater than the proportion of missing data, as per White et al. \[[@CR30]\]. A complete case analysis was also undertaken for comparative purposes.

We estimated the incremental difference in mean total costs and mean QALYs between the two arms of the trial and 95% confidence intervals using ordinary least squares regression. In the primary analysis, cost and QALY data were combined to calculate a NMB statistic \[[@CR31]\] from the NHS and PSS perspective. For each individual *i*, the NMB statistic is NMB~*i*~ = *λE*~*i*~ − *C*~*i*~, where *C*~*i*~ is the cost of care for that individual, *E*~*i*~ is the QALYs of that individual, and *λ* is the cost-effectiveness threshold (i.e. the amount society is willing to pay for a QALY). In all analyses, we used the commonly used NICE threshold values of £20,000 and £30,000 per QALY. We estimated NMB regressions using interactions between the treatment indicator and baseline severity (model 1) and in a separate model between the treatment indicator and symptom duration (model 2) to explore whether sertraline was differentially more cost-effective across subgroups defined by symptom severity or duration. Three severity strata (0--11; 12--19; 20+ on the Clinical Interview Schedule---Revised (CIS-R) at baseline) \[[@CR32]\] and two duration strata (less than 2 years or 2 years or more) were prespecified in the trial protocol \[[@CR17]\]. The CIS-R is a widely used diagnostic assessment tool for mental health conditions. The CIS-R score indicates the severity of psychological symptoms. A positive regression coefficient on the interaction term between the treatment group and patient subgroup indicates that sertraline is potentially more cost-effective in that subgroup compared with the reference subgroup.

In a prespecified secondary analysis, we estimated the cost-effectiveness of sertraline versus placebo (model 3), irrespective of baseline severity and symptom duration. All regression models adjusted for baseline utility scores and study centre as a random effect. Uncertainty in the point estimates of NMB was quantified using 95% confidence intervals estimated from the regressions. We calculated cost-effectiveness acceptability curves (CEACs) \[[@CR33]\] to probe the uncertainty in the optimal treatment for various different cost-effectiveness thresholds.

In a post-hoc sensitivity analysis, we examined the impact of excluding secondary care and prescriptions extracted from medical records that were judged to be not clearly related to the treatment of depression (Supplementary Table 1 in the Electronic supplementary material, ESM). We also conducted a further sensitivity analysis in which we removed all secondary care costs from total NHS and PSS costs. This assessed whether our findings were robust to infrequent but expensive hospitalisations that might differ between arms by chance.

The economic evaluation followed best practice guidelines, as outlined by Husereau et al. \[[@CR34]\] and detailed in Supplementary Table 2 in the ESM. Stata software (version 15) \[[@CR35]\] was used for all analyses.

Results {#Sec6}
=======

Patient Characteristics and Trial Outcomes {#Sec7}
------------------------------------------

We randomised 655 patients, 326 to sertraline and 329 to placebo. Two patients were missing substantial proportions of the baseline assessment and were excluded, leaving 653 for analyses. 505 (77.3%) patients had complete EQ-5D-5L responses at all four assessment points. A smaller proportion (381/653; 58.3%) had complete resource use data available from primary care notes and self-reported assessments. Follow-up rates were similar in both arms at all time points (Supplementary Fig. 1 in the ESM). At recruitment, the mean age was 39.7 years (SD 14.96), 59% (*n* = 384) were female, and the mean PHQ-9 score was 12.0 (SD 5.8) \[[@CR16]\]. Table [1](#Tab1){ref-type="table"} provides details of baseline PHQ-9 scores and EQ-5D-5L scores across the subgroups defined by severity and duration. At baseline, patients with severe or prolonged depressive symptoms (≥ 2 years) had worse EQ-5D-5L and PHQ-9 scores. As previously reported, there was a 5% relative reduction (adjusted proportional change 0.95 \[95% CI 0.85--1.07\]) in PHQ-9 depressive symptom scores in the sertraline group at 6 weeks, but the confidence interval did not exclude the possibility of no treatment effect \[[@CR16]\]. There was stronger evidence for a treatment effect of sertraline on PHQ-9 score at 12 weeks (adjusted proportional change 0.87 \[95% CI 0.79--0.97\]) \[[@CR16]\]. In the sections below, we first report the cost-effectiveness of sertraline versus placebo (secondary analysis) and then explore whether sertraline was differentially more cost-effective across subgroups defined by symptom severity or duration (primary analyses).Table 1Baseline health-related quality of life in subgroups defined by depressive symptom severity and durationSertraline (*n* = 324)Placebo (*n* = 329)Overall (*n* = 653)Mean (SE)Mean (SE)Mean (SE)Severity subgroups EQ5D-5L  Mild (*n* = 129)0.816 (0.014)0.796 (0.017)0.806 (0.011)  Moderate (*n* = 173)0.769 (0.016)0.800 (0.012)0.785 (0.010)  Severe (*n* = 349)0.652 (0.016)0.653 (0.016)0.653 (0.011) PHQ-9  Mild (*n* = 128)5.657 (0.410)6.049 (0.548)5.844 (0.337)  Moderate (*n* = 173)9.500 (0.432)10.258 (0.420)9.890 (0.302)  Severe (*n* = 350)15.308 (0.370)15.275 (0.349)15.291 (0.254)Duration subgroups EQ5D-5L  \< 2 years (*n* = 439)0.729 (0.012)0.743 (0.012)0.736 (0.009)  ≥ 2 years (*n* = 212)0.690 (0.020)0.673 (0.020)0.681 (0.014) PHQ-9  \< 2 years (*n* = 438)11.408 (0.400)11.550 (0.388)11.479 (0.278)  ≥ 2 years (*n* = 213)12.600 (0.567)13.519 (0.521)13.066 (0.385)

Cost-Effectiveness (Sertraline Versus Placebo) {#Sec8}
----------------------------------------------

In the imputed dataset, total NHS and PSS costs were lower in the sertraline group (£154) than in the placebo group (£177), but the difference was small and there was no evidence of a treatment effect on costs (difference − £22 \[95% CI − £87 to £42\]; *p* value 0.490) (Table [2](#Tab2){ref-type="table"}). Sensitivity analyses excluding secondary care costs and costs not clearly associated with mental health care supported this finding, as did the complete case analysis. There was little difference in patient costs or time off work costs (i.e. productivity losses) between groups. The cost of sertraline in the intervention group over the 12 weeks of the trial was minimal. There were no large or consistent differences in the cost of other medications, primary care consultations, community-based care or hospital care between the sertraline or placebo groups during the 12-week follow-up.Table 2Summary costsSertraline (*n* = 324)Placebo (*n* = 329)Mean difference (*n* = 653)Mean (SE)^c^Mean (SE)^c^Mean (95% CI)*p* valueImputed Total NHS costs^a^£154.01 (£18.97)£176.5 (£25.71)£− 22.48 (− £86.61 to £41.64)0.490 Total NHS mental-health-related costs^b^£35.26 (£7.96)£55.12 (£12.11)£− 19.86 (− £49.16 to £9.44)0.182 Total NHS costs, excluding secondary care£98.39 (£14.92)£121.43 (£15.58)£− 23.04 (− £65.19 to £19.12)0.283 Total productivity losses£134.38 (£32.27)£120.58 (£25.93)£13.8 (− £68.03 to £95.63)0.740 Total patient costs£4.73 (£2.55)£7.93 (£2.68)£− 3.2 (− £10.46 to £4.06)0.386Sertraline (*n* = 174)Placebo (*n* = 207)Mean difference (*n* = 381)Mean (SD)Mean (SD)Mean (95% CI)*p* valueComplete cases Total NHS costs^a^£169.34 (£351.17)£188.42 (£423.05)− £19.08 (− £98.33 to £60.16)0.636 Total NHS mental-health-related costs^b^£28.98 (£93.65)£50.92 (£167.33)− £21.94 (− £49.98 to £6.1)0.125 Total NHS costs, excluding secondary care£112.18 (£303.14)£124.36 (£274.77)− £12.18 (− £70.44 to £46.07)0.681 Total productivity losses£118.22 (£484.05)£69.61 (£246.46)£48.6 (− £27.05 to £124.26)0.207 Total patient costs£5.41 (£41.52)£10.83 (£47.24)− £5.42 (− £14.46 to £3.62)0.239Disaggregated costs (complete cases) Sertraline£3.81 (£0.62)£0 (£0)£3.81 (£3.72 to £3.89)0.000 Primary care consultations  GP consultations£26.16 (£44.48)£27.53 (£39.55)− £1.37 (− £9.84 to £7.1)0.750  Nurse consultations£3.93 (£13)£5.14 (£11.3)− £1.21 (− £3.66 to £1.24)0.332  GP telephone calls£3.23 (£8.55)£2.72 (£8.69)£0.52 (− £1.23 to £2.26)0.562  Nurse telephone calls£0.5 (£2.43)£0.65 (£3.28)− £0.15 (− £0.74 to £0.44)0.620 Medications  All£49.61 (£272.99)£37.64 (£215.99)£11.97 (− £37.31 to £61.25)0.633  Mental health£0.23 (£1.46)£0.23 (£2.2)£0 (− £0.39 to £0.38)0.995 Secondary care  Inpatient care£3.55 (£46.78)£20.71 (£258.4)− £17.16 (− £56.21 to £21.89)0.388  Outpatient care£35.83 (£93.22)£33.39 (£102.76)£2.44 (− £17.49 to £22.36)0.810  Accident and emergency£17.78 (£85.67)£9.97 (£42.4)£7.82 (− £5.48 to £21.12)0.249 Community-based care  Community care£23.6 (£90.59)£47.99 (£164.74)− £24.39 (− £51.9 to £3.11)0.082  Home visits£1.33 (£14.68)£2.45 (£30.18)− £1.12 (− £6.05 to £3.81)0.655  Additional help£0.02 (£0.23)£0.25 (£2.88)− £0.23 (− £0.66 to £0.2)0.296*CI* confidence interval, *NHS* National Health Service, *PSS* Personal and Social Services, *SD* standard deviation, *SE* standard error^a^Primary, secondary, and community-based care^b^Mental-health-related medication and community care costs^c^Standard errors reported here are due to imputed datasets

Over the 12-week period, QALYs were marginally higher in the sertraline group (0.182) than the placebo group (0.177), but there was no strong evidence of a treatment effect using the imputed dataset (QALY difference 0.005 \[95% CI − 0.003 to 0.012\]; *p* value 0.150) (Table [3](#Tab3){ref-type="table"}). However, preference-based quality of life scores measured by the EQ-5D-5L increased (i.e. improved) in both groups from baseline to 12 weeks. There was some evidence that sertraline was more cost-effective than placebo at a threshold of £20,000 (incremental NMB £122 \[95% CI £18 to £226\]; *p* value 0.022) and £30,000 (incremental NMB £171 \[95% CI £33 to £310\]; *p* value 0.016) per QALY, respectively (Table [4](#Tab4){ref-type="table"}, model 3); sertraline had a high probability (\> 95%) of being cost-effective if the health system is willing to pay more than £20,000 per QALY gained (Fig. [1](#Fig1){ref-type="fig"}).Table 3Utility scores and QALYsSertraline (*n* = 324)Placebo (*n* = 329)Mean difference (*n* = 653)Mean (SE)Mean (SE)Mean (95% CI)*p* valueImputed QALYs0.182 (0.002)0.177 (0.002)0.005 (− 0.003 to 0.012)0.150Sertraline (*n* = 248)Placebo (*n* = 257)Mean difference (*n* = 505)Mean (SD)Mean (SD)Mean (95% CI)*p* valueComplete cases Baseline0.732 (0.172)0.725 (0.188)0.008 (− 0.024 to 0.039)0.638 2 weeks0.774 (0.164)0.756 (0.176)0.018 (− 0.012 to 0.048)0.236 6 weeks0.807 (0.180)0.776 (0.185)0.031 (− 0.001 to 0.063)0.054 12 weeks0.815 (0.184)0.790 (0.185)0.025 (− 0.007 to 0.057)0.128 QALYs0.183 (0.034)0.178 (0.037)0.006 (− 0.002 to 0.013)0.078*CI* confidence interval, *QALYs* quality-adjusted life years, *SD* standard deviation, *SE* standard errorTable 4Incremental net monetary benefit results (imputed)£20,000 WTP£30,000 WTPINMB (95% CI)*p* valueINMB (95% CI)*p* valueModel 1 (*n* = 650) Sertraline£91.94 (− £123.17 to £307.06)0.401£129.23 (− £150.48 to £408.94)0.364 Severity  LowReferenceReference  Moderate− £33.55 (− £275.23 to £208.13)0.785− £56.28 (− £354.6 to £242.04)0.711  High− £58.02 (− £337.46 to £221.42)0.683− £95.19 (− £457.35 to £266.98)0.605 Sertraline × severity  LowReferenceReference  Moderate£24.18 (− £279.96 to £328.31)0.876£47.23 (− £341.78 to £436.24)0.811  High£37.44 (− £221.35 to £296.24)0.776£44.46 (− £304.27 to £393.19)0.802Model 2 (*n* = 650) Sertraline£127.41 (− £2.25 to £257.08)0.054£177.96 (£9.14 to £346.78)0.039 Duration (\> 2 years)£26.61 (− £125.95 to £179.18)0.732£10.71 (− £196.18 to £217.61)0.919 Sertraline × duration (\> 2 years)− £27.14 (− £258.13 to £203.86)0.817− £37.39 (− £360.59 to £285.81)0.820Model 3 (*n* = 653) Sertraline vs placebo£121.83 (£17.79 to £225.87)0.022£171.12 (£32.68 to £309.55)0.016Model 1: interaction model between sertraline and baseline severity, adjusted for severity, duration, baseline utility and site practiceModel 2: interaction model between sertraline and duration, adjusted for duration, severity, baseline utility and site practiceModel 3: non-interaction model comparing sertraline vs placebo, adjusted for baseline utility and site practice*CI* confidence interval, *INMB* incremental net monetary benefitFig. 1Cost effectiveness acceptability curve of sertraline versus placebo (imputed)

Cost-Effectiveness (in Subgroups Defined by Symptom Severity and Duration) {#Sec9}
--------------------------------------------------------------------------

Participants with higher symptom severity reported lower utility scores during trial follow-up (Table [5](#Tab5){ref-type="table"}), although several patients reported high QALY scores despite high baseline symptom severity (Supplementary Fig. 2 in the ESM). QALYs were slightly higher in the sertraline group in all three depressive symptom severity strata, but in each case the confidence interval included zero (Table [5](#Tab5){ref-type="table"}). There were no consistent differences in the incremental costs of sertraline across all three symptom strata, and confidence intervals were wide (Table [5](#Tab5){ref-type="table"}).Table 5Costs and outcomes in subgroups defined by depressive symptom severity (complete cases except where stated)SertralinePlaceboDifferenceMean (SD)Mean (SD)Mean (95% CI)Mild (*n* = 103) Baseline utility score0.815 (0.121)0.806 (0.121)0.009 (− 0.038 to 0.057) 2 weeks utility score0.842 (0.112)0.825 (0.139)0.016 (− 0.032 to 0.067) 6 weeks utility score0.874 (0.138)0.843 (0.131) 0.030 (− 0.022 to 0.083) 12 weeks utility score0.893 (0.123)0.860 (0.133)0.033 (− 0.017 to 0.083)QALYs (imputed, *n* = 129)0.199 (0.003 SE)0.192 (0.004 SE)0.004 (− 0.004 to 0.012)Total NHS costs (imputed, *n* = 129)£163.22 (£36.46 SE)£188.65 (£58.71 SE)− £18.92 (− £154.15 to £116.31)Incremental NMB^a^ (imputed, *n* = 129)£101.83 (− £113.68 to £317.34)Moderate (*n* = 137) Baseline utility score0.776 (0.134)0.792 (0.117)− 0.017 (− 0.059 to 0.026) 2 weeks utility score0.814 (0.163)0.808 (0.101)0.006 (− 0.040 to 0.052) 6 weeks utility score0.835 (0.183)0.828 (0.132)0.007 (− 0.046 to 0.061) 12 weeks utility score0.861 (0.163)0.810 (0.157)0.051 (− 0.003 to 0.105)QALYs (imputed, *n* = 173)0.191 (0.004 SE)0.189 (0.003 SE)0.007 (0 to 0.014)Total NHS costs (imputed, *n* = 173)£175.5 (£50.35 SE)£160.03 (£56.17 SE)£3.65 (− £145.04 to £152.35)Incremental NMB^a^ (imputed, *n* = 173)£134.56 (− £69.39 to £338.51)Severe (*n* = 265) Baseline utility score0.676 (0.187)0.660 (0.213)0.016 (− 0.032 to 0.065) 2 weeks utility score0.726 (0.168)0.704 (0.202)0.022 (− 0.023 to 0.067) 6 weeks utility score0.766 (0.183)0.724 (0.209)0.041 (− 0.006 to 0.089) 12 weeks utility score0.760 (0.198)0.754 (0.206)0.006 (− 0.043 to 0.055)QALYs (imputed, *n* = 351)0.171 (0.003 SE)0.166 (0.003 SE)0.005 (− 0.002 to 0.011)Total NHS costs (imputed, *n* = 351)£140.02 (£18.59 SE)£180.5 (£28.41 SE)− £40.7 (− £108.63 to £27.24)Incremental NMB^a^ (imputed, *n* = 351)£131.18 (− £18.49 to £280.86)^a^At £20,000 per QALY threshold

There was no evidence of an association between the baseline severity of depressive symptoms and the cost-effectiveness of sertraline (Table [4](#Tab4){ref-type="table"}, model 1). Compared to patients with low symptom severity at baseline, patients with moderate symptoms (difference in incremental NMB £24 \[95% CI − £280 to £328\]; *p* value 0.876) and patients with high symptom severity had higher incremental net benefits of sertraline (difference in incremental NMB £37 \[95% CI − £221 to £296\]; *p* value 0.776). Similar findings were observed at the £30,000 per QALY threshold. Sertraline was probably (*p* \> 0.7) cost-effective in all three severity subgroups at the £20,000 per QALY threshold (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Cost-effectiveness acceptability curves of sertraline versus placebo in patients with different levels of severity of depression (imputed)

There was little obvious association between symptom duration and QALYs or costs (Supplementary Fig. 2 in the ESM). QALYs were slightly higher in the sertraline group in both strata of symptom duration, but the confidence intervals approached zero (Table [6](#Tab6){ref-type="table"}). The NHS costs were lower in the sertraline group in both strata, but the confidence intervals were wide and included zero (Table [6](#Tab6){ref-type="table"}). Patients who had a longer history of depressive symptoms at baseline (Table [4](#Tab4){ref-type="table"}, model 2) had lower incremental net benefits from sertraline than those with a shorter history; however, the confidence intervals were wide (difference in incremental net benefit − £27 \[95% CI − £258 to £204\] at the £20,000 per QALY threshold; *p* value 0.817). The probability that sertraline is cost-effective in those with longer symptom duration exceeds 0.8 (Fig. [3](#Fig3){ref-type="fig"}).Table 6Costs and outcomes in subgroups defined by symptom duration (complete cases except where stated)SertralinePlaceboDifferenceMean (SD)Mean (SD)Mean (95% CI)\< 2 years (*n* = 342) Baseline utility score0.732 (0.182)0.734 (0.182)− 0.003 (− 0.041 to 0.036) 2 weeks utility score0.774 (0.176)0.764 (0.170)0.011 (− 0.026 to 0.048) 6 weeks utility score0.813 (0.194)0.782 (0.191)0.031 (− 0.010 to 0.072) 12 weeks utility score0.837 (0.170)0.808 (0.181)0.029 (− 0.008 to 0.067)QALYs (imputed, *n* = 439)0.185 (0.003 SE)0.181 (0.002 SE)0.006 (0.001 to 0.01)Total NHS costs (imputed, *n* = 439)£168.6 (£24.76 SE)£192.2 (£33.33 SE)− £23.6 (− £106.11 to £58.92)Incremental NMB (imputed, *n* = 439)£139.72 (£11.39 to £268.06)≥ 2 years (*n* = 163) Baseline utility score0.733 (0.151)0.703 (0.200)0.030 (− 0.024 to 0.085) 2 weeks utility score0.774 (0.138)0.740 (0.189)0.034 (− 0.017 to 0.085) 6 weeks utility score0.796 (0.147)0.763 (0.172)0.033 (− 0.017 to 0.082) 12 weeks utility score0.771 (0.204)0.750 (0.189)0.021 (− 0.040 to 0.082)QALYs (imputed, *n* = 214)0.175 (0.004 SE)0.169 (0.004 SE)0.005 (− 0.004 to 0.013)Total NHS costs (imputed, *n* = 214)£124.02 (£21.63 SE)£144.37 (£31.65 SE)− £17.66 (− £92.59 to £57.27)Incremental NMB (imputed, *n* = 214)£107.95 (− £79.84 to £295.74)Fig. 3Cost-effectiveness acceptability curves of sertraline versus placebo in patients with different levels of symptom duration (imputed)

Sensitivity Analyses {#Sec10}
--------------------

Restricting the analysis to patients with complete data did not change the conclusions (Supplementary Table 3 in the ESM). The results remained unchanged in sensitivity analyses in which secondary care costs and costs not clearly associated with mental health care were excluded (Supplementary Tables 4 and 5 in the ESM).

Discussion {#Sec11}
==========

Key Findings {#Sec12}
------------

We found insufficient evidence that variation in the cost-effectiveness of sertraline according to severity or symptom duration at prespecified thresholds could be used by GPs to target prescribing to subgroups of patients. There was no evidence of a substantial treatment effect of sertraline on quality of life as measured by the EQ-5D-5L. However, sertraline is a cheap intervention that had a high probability of being cost-effective compared with placebo, on average, across primary care patients with depression or low mood.

Strengths and Weaknesses {#Sec13}
------------------------

The PANDA trial is a large publicly funded, placebo-controlled trial of an antidepressant. We used pragmatic eligibility criteria to recruit participants where the GP was uncertain about the benefit of an SSRI, which resulted in randomised patients ranging from those with very few to those with severe depressive symptoms. The wide spectrum of symptom severity and duration increased the likelihood of identifying subgroups where sertraline was more cost-effective. The PANDA trial had a relatively short follow-up period and found no strong evidence that sertraline reduced depressive symptoms measured by the primary outcome (PHQ-9) at 6 weeks \[[@CR16]\]. While there was evidence that sertraline reduced depressive symptoms by 12 weeks and reduced anxiety at 6 and 12 weeks, there was no evidence that symptom severity or duration affected response to either depressive or anxious symptoms \[[@CR16]\]. Adverse events were rare (four adverse events for sertraline and three for placebo) \[[@CR16]\]. In this paper, we have demonstrated that utility scores based on the EQ-5D-5L were marginally higher in the sertraline group at 6 and 12 weeks, although we cannot definitively exclude no treatment effect. We used the newer five-level version of the EQ-5D, which was developed to be more sensitive to changes in health status. However, it is possible that subgroups where sertraline was more cost-effective might have become more evident with longer follow-up or a more sensitive preference-based outcome measure.

Although the PANDA trial is, to our knowledge, the largest trial of an antidepressant to explore differential cost-effectiveness across prespecified subgroups, it was not designed to provide high statistical power on the economic outcome (NMB). Cost-effectiveness outcomes are often measured with less precision than clinical outcomes due to skewed cost distributions (through rare high-cost events) and a higher prevalence of missing data (as cost and QALY data are cumulative measures requiring complete data at every follow-up point). Approximately 40% of patients had at least one missing data point for resource use in the PANDA trial. This proportion is not unusual in primary care trials recruiting patients with depressive symptoms \[[@CR36]\]. We assumed data were missing at random and used multiple imputation methods to minimise the risk of bias due to missing data. Nevertheless, missing data reduce the precision of our estimates and decrease the statistical power to identify differential cost-effectiveness across subgroups. We also analysed the two subgroup variables of severity and duration separately, but this neglects any correlation between them (e.g. in those for whom severity is related to duration).

We prespecified symptom severity and duration thresholds in order to reduce the risk of a type 1 error, which could occur if multiple tests are used to compare subgroups defined by a large number of different severity and duration threshold values. However, the prespecified thresholds are essentially arbitrary values with "sharp" cut-off points, and it is possible that other threshold values might have better differentiated between subgroups where sertraline is more or less cost-effective. The PANDA trial only explored one of a large number of potential treatment options for primary care patients with depressive symptoms. The cost-effectiveness of other options, such as cognitive behavioural therapy, might also plausibly vary with symptom severity and duration. The expansion of access to psychological therapy increases the number of treatment options available and also the complexity of selecting the optimal treatment for patient subgroups \[[@CR37]\].

Comparison with Other Studies {#Sec14}
-----------------------------

Guidelines for conducting economic evaluations alongside RCTs emphasise the value of subgroup analyses for decision makers and the importance of subgroup prespecification to minimise false-positive findings \[[@CR38]\]. The National Institute of Health and Care Excellence (NICE) encourages estimates of the interaction between the treatment effect and prespecified, clinically plausible subgroups to identify patient characteristics that increase or decrease the cost-effectiveness of the intervention \[[@CR39]\]. However, NICE and other method guides \[[@CR38]\] do not specify how cost-effectiveness subgroup analyses should be conducted or interpreted. Further methodological guidance is needed in this area. The decision-making approach, focussing on mean net benefits irrespective of statistical significance, could be applied to subgroup analyses \[[@CR40]\], and would probably lead to coverage decisions based on a larger number of subgroups.

NICE note that not all patient subgroups (for example those defined by socioeconomic status) will provide an equitable basis for policy making, even if they are strongly associated with the intervention net benefit. The appropriate use of subgroups can increase population health by targeting spending at those patients where health gains are highest and/or opportunity costs are lowest \[[@CR41]\]. In order to achieve this, subgroups need to be defined by characteristics that can be easily and objectively identified in clinical practice; in principle the severity and duration of depressive symptoms fit these criteria. Given the high cost and clinical uncertainty surrounding the appropriate prescribing of antidepressants in primary care, it is surprising that there is not a larger literature identifying subgroups where SSRIs are most (and least) cost-effective.

Previous work based on the THREAD RCT explored how the cost-effectiveness of an SSRI and supportive care versus supportive care alone in primary care patients with new episodes of mild to moderate depression might vary by patient subgroup \[[@CR42], [@CR43]\]. That work identified an association between previous episodes of depression and the costs and QALY outcomes of treatment. Based on a comparison of CEACs by subgroup, they concluded that having no previous episode of depression was associated with a higher probability of the SSRI being cost-effective. Our findings, based on a larger sample size and a prespecified hypothesis, provide limited support for this finding. We found that while the incremental net benefit of sertraline was lower in patients with a longer duration of symptoms, the confidence intervals were wide and included zero (i.e. no interaction between duration and cost-effectiveness).

Implications for Practice and Research {#Sec15}
--------------------------------------

It remains plausible that the cost-effectiveness of SSRIs is related to the duration of symptoms, but our data do not provide sufficient evidence that a threshold symptom duration of 2 years could be used to target prescribing. Individual patient data meta-analysis of SSRI RCTs (e.g. PANDA and THREAD) with economic evaluations could increase the power to detect meaningful subgroups. In practice, though, the lack of homogeneity between these trials (for example the use of a placebo control and the method used to measure QALYs) may limit the viability of this approach. This could improve with increased data sharing and the adoption of core cost and outcome sets in future trials.

Our findings demonstrate that sertraline is probably cost-effective relative to placebo on average across the broad range of depressive symptom severities included in the PANDA trial. However, individual treatment decisions must assess the potential benefits and harms of sertraline. Caution and careful treatment monitoring is particularly required in young adults, where evidence suggests an increased risk of suicidal ideation with SSRI use \[[@CR44], [@CR45]\]. There was insufficient evidence that the use of sertraline was differentially cost-effective in any of the three severity subgroups explored in the PANDA economic analysis.

The relatively small differences in cost and outcomes observed between the sertraline and placebo groups will probably continue to make it difficult to identify subgroups where SSRI prescribing is markedly more cost-effective. Subgroup analyses based on economic evaluation may be more likely to be of value to policy makers in situations where the cost/efficacy/safety trade-offs are higher and where net benefit is more strongly associated with subgroup characteristics. In these cases, statistical power will be improved, although large sample sizes will still be required to identify interactions with baseline characteristics.

Conclusions {#Sec16}
===========

There is currently insufficient evidence that the cost-effectiveness of sertraline differs between subgroups defined by symptom severity and duration. Given this, it is likely that clinical judgement and patient preferences will continue to play the predominant role in the initiation of SSRI prescribing.
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